Latest revenue
$0
as of 2022-12-31
Latest net income
$-353.6K
as of 2022-12-31
Net margin
—
as of 2022-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think AGTX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $841.4K
- Enterprise value
- $829.0K
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.06
- 52-wk low
- $0.02
- Beta
- —
- Shares out
- 40.1M
5-year trend
What this company does
Item 1. Business. History The Company was incorporated in the State of Nevada on April 18, 2013 and has established a fiscal year end of March 31. Effective June 17, 2019, we changed our name from FairWind Energy, Inc. to Agentix Corp. and to better reflect the new focus of our business. We are a clinical development stage corporation with a focus on pharmaceutical treatments in the metabolic disease space and have not yet generated or realized meaningful revenues from our business. Until recently, our business plan focused on the design, engineering and manufacturing of composite products, specifically the supply products to the oil and gas industry. However, on May 28, 2020, entered into…
AI summary unavailable — showing raw filing excerpt
Generated from AGTX's filing dated 2025-07-16
Key risks
Item 1A. Risk Factors. As a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.
AI summary unavailable — showing raw filing excerpt
Generated from AGTX's filing dated 2025-07-16
Profitability
Gross margin
54.8%
0.0%Operating margin
-211825.1%
95.9%Net margin
-211825.1%
96.0%Return on equity
18.3%
20.1%Return on assets
-565.5%
2.8%Leverage
Debt / equity
-1.03×
0.9%Debt / assets
3195.8%
27.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $-78.6K | +45.4% | — |
Q3 2025 2025-09-30 | — | — | $-144.1K | -58.9% | — |
Q1 2025 2025-03-31 | — | — | $-181.8K | -5963.0% | — |
Q4 2024 2024-12-31 | — | — | $-143.9K | -2357.5% | — |
Q3 2024 2024-09-30 | — | — | $-90.7K | +49.3% | — |
Q2 2024 2024-06-30 | — | — | $-150.7K | +63.2% | — |
Q1 2024 2024-03-31 | — | — | $-3.0K | — | — |
Q4 2023 2023-12-31 | — | — | $6.4K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on AGTX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for AGTX in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns AGTX
No institutional holdings on file for AGTX yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once AGTX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.